Chemotherapy gel for T-cell skin lymphoma approved for NHS use in England and Wales

NICE has approved chlormethine gel for NHS use for adults with mycosis fungoides.

NICE logo

The National Institute for Health and Care Excellence has today (15 July) announced that chlormethine gel will be available on the NHS for adults with early-stage mycosis fungoides in England and Wales. Northern Ireland usually follows NICE recommendations. The Scottish Medicines Consortium has already approved chlormethine gel for NHS use in Scotland.

Chlormethine gel is a chemotherapy drug that is applied directly to the skin. It has been found to be effective for people with early-stage mycosis fungoides, a slow-growing (low-grade) type of T-cell skin lymphoma.

In its draft recommendation, NICE had concluded that chlormethine gel should not be made available on the NHS. Lymphoma Action and other organisations opposed this recommendation and we are delighted that NICE has reconsidered its recommendation.

 
We are delighted that NICE has reconsidered its decision on chlormethine gel. Today’s positive recommendation means this effective, convenient treatment is available on the NHS for people affected by early-stage mycosis fungoides throughout the UK.
Ropinder Gill, Chief Executive of Lymphoma Action

For more information about new drugs being developed to treat lymphoma, visit Lymphoma TrialsLink.

Posted: 15 July 2021